Following questions about the integrity of clinical trial data, regulators in Europe are taking a second look at Tavneos (avacopan), an oral therapy approved for ANCA-associated vasculitis (AAV). In a press release, the European Medicines Agency (EMA) announced that it “will now review all available data to…